Veracyte Q2 revenue up 15% to $150.3M; launches Prosigna and TrueMRD

VERACYTE, INC.

Total revenue $150.3M (+15% YoY); testing revenue $145.7M (+19%); Decipher +20%, Afirma +18%.
GAAP net income $25.5M (17% of revenue); adjusted EBITDA $44.0M (29.2% of revenue).
Launched Prosigna LDT for early-stage HR+ breast cancer and TrueMRD for MIBC; secured Medicare coverage for TrueMRD.
Cash from ops $45.8M; cash & investments $485.2M as of June 30, 2026.
Total testing volume up 14% to 48,389 tests; Decipher tests +17%, Afirma +10%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.